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target populations; 3) the need for fast, iterative assessments of technologies from 
development to implementation stages; 4) the need for ready available repositories 
of (country-specific) epidemiology and cost data; and 5) the need to extrapolate 
results over time and settings. To address these challenges, the Joint Research Center 
(JRC) of the European Commission has commissioned the construction of an online 
tool that allows stakeholders of the EIP on AHA to estimate the health economic 
impact of their interventions in real-time. At the core of this tool is a generic, highly 
adaptable Markov model with three mutually exclusive health states (‘baseline 
health’, ‘deteriorated health’ and ‘death’), combined with an extensive database of 
epidemiological, economic and effectiveness data. The tool assesses the impact of 
an innovation on resource use (both from a healthcare and societal perspective) and 
the Health Related Quality of Life of patients. We demonstrate the application and 
discuss the value of the tool using a case study from the EIP on AHA, on the develop-
ment of a falls prediction device. An early assessment (prior to clinical testing) was 
performed to estimate the possible impact of this intervention, considering various 
implementation scenarios. Finally, we will discuss the conceptual and practical nov-
elty as well as the (scientific) challenges of this approach for informing healthcare 
decisions regarding research funding, innovation development and implementation.
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Objectives: Capturing QOL information in orphan indications presents multiple 
barriers. Patient recruitment is challenging due to low incidence and severity 
of the condition. An additional consideration is the inability to make statistical 
inference due to low sample sizes. Outcomes research teams must consider novel 
methods for optimizing data collection and analysis within these populations. This 
case study evaluates the methods to address QOL data gaps in RR-DTC, a hard-to-
treat, rare cancer. MethOds: In a real-world observational study of patients with 
RR-DTC, a mixed-methods quantitative survey and qualitative data collection is 
being conducted to ascertain direct patient feedback through survey data collection 
and patient interviews. Sampling of patients is being done from the target popu-
lation in a real-world setting. This mixed-methods approach allows for an all-
encompassing understanding of the patient’s treatment experience and relevance 
of qualitative change to quantitative reporting within the clinical trial. Study docu-
ments capture symptoms and impact data cross-sectionally and longitudinally 
and to allow for the cross-linking of survey results to the clinical data. Results: 
Data will be presented on a sample of 120 patients: 50 currently undergoing sys-
temic therapy with sorafenib, 50 with lenvatinib, and 20 receiving no systemic 
therapy. QOL endpoints include the Functional Assessment of Cancer Therapy-
General (FACT-G), EQ-5D-5L, Symptoms & Toxicities experience, Impressions of 
Treatment Satisfaction, and Subject Preference. In addition, data from qualita-
tive interview of 40 patients will be presented to fully conceptualize quality of 
survival. The methods for patient recruitment and barriers to implementation 
will be presented as well as mixed methodology for interpreting quantitative 
survey data using supportive qualitative information. cOnclusiOns: In absence 
of phase 3 QOL data in rare indications, a mixed-method approach utilizing real-
word observational study can yield important information that supports previ-
ously demonstrated survival benefit and help our understanding of treatment 
impact on quality of survival.
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Objectives: Drug authorization in Germany is regulated by the early benefit assess-
ment based on the risk-benefit ratio according to IQWiG General Methods. For con-
sumer goods, the Federal Institute for Risk Assessment (BfR) evaluates the risk by 
quantifying potential hazards and the exposure. Investigation regarding the gap 
between the assessments has rarely been done. This article aims to give a profound 
understanding of the concepts from IQWiG and BfR, and an initial recommendation 
to fill the gap. MethOds: The IQWiG General Methods and the BfR guidance for 
risk assessment are reviewed to compare their frameworks and evidence stand-
ards. Based on the results of the comparison, a product Xthat fits the gap between 
drugs and consumer goods is simulated and methods that fills the gap are recom-
mended. Results: Risk/Benefit assessment according to IQWiG is rigorously based 
on the Evidence Based Medicine (EBM) standards, while risk assessment accord-
ing to BfR has a clear focus on transparency of research. Risk/benefit according to 
IQWiG is assessed via patient-relevant endpoints, which is not applicable to the risk 
assessment of most consumer goods according to BfR. Recommendations for the 
simulated product Xinclude the adaption of the evidence standard, re-definition 
of risk and benefit and the application of mathematical models. cOnclusiOns: 
Various gaps exist between risk/benefit assessment for drugs and risk assessment 
for consumer goods. As more and more emerging products are waiting for the mar-
ket launch, a new guidance that fills the gap and is applicable for these products 
would be highly necessary.
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Pharmaceutical sponsors strive to capture the patient voice during drug develop-
ment. One emerging trend is the role that patient advocates can play in influencing 
regulatory decision making, often through powerful and emotive testimonials at 
the ‘probabilistic sensitivity analysis’ sample: a single set of samples from the model 
parameters, along with the corresponding modelled costs and health outcomes. 
The only extra requirement for EVSI is the ability to simulate study data. There is 
no need to re-run the model in either case. We have made available an easy-to-use, 
open access, web-based Value of Information calculator called ‘SAVI’ http://savi.shef.
ac.uk/SAVI. CONCLUSION: Value of Information measures can now be computed 
quickly for models of any complexity, and hence be made more widely available to 
modellers and decision makers.
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Objectives: Detailed data on type 2 diabetes mellitus (T2DM) patients and treat-
ment in clinical practice are scarce. The Nordic region offers unique opportunities 
for research on patient-level data from various complementary data sources, by 
availability of homogenous public healthcare systems with clinical information 
registered in electronic medical records (EMR) and mandatory national registers, and 
data linkage using the unique personal identification numbers for all inhabitants. 
This paper describes the implementation of a novel research methodology utilized 
in the Nordic countries to provide new T2DM insights based on a hybrid utilization of 
EMR data combined with national health registers, and supports the ongoing global 
DISCOVER program (NCT02322762). MethOds: This observational study collects 
both prospective health care data and retrospective longitudinal data. Patient-level 
information (e.g. demographics, diagnoses, clinical notes, laboratory results, health 
care contacts and referrals) of the enrolled T2DM patients will be extracted from EMR 
at each study site. To facilitate clinical data completeness, specific variables will be 
collected by electronic case report forms. In addition, the national full population 
registers (patient-, cause of death- and prescribed drug registers) provide longitudi-
nal data for the enrolled T2DM patients, the complete study site T2DM cohorts, and 
the nationwide full T2DM population. Results: This approach, bridging data from 
the enrolled T2DM patients, the complete cohort of T2DM patients at the study sites, 
and the nationwide full population, generates extended observational data with 
high internal and external validity from approximately 1 million T2DM patients. 
Iterative data collection spanning several years (2015 – 2018), thus potentiating 
interim analyses, will provide contemporary insights of T2DM disease progression 
and treatment development. cOnclusiOns: This novel methodology presents a 
new era for observational research, providing efficient ways of generating com-
prehensive data with high completeness and minimal interference with ordinary 
clinical practice. This is highly relevant for diabetes and other chronic diseases.
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bAckgROund: What distinguishes informative health outcomes from all other 
measures of health is whether these are based on the perception and preferences 
of patients. New HRQoL preference-based measurement methods that use the 
patient’s own evaluations as the point of reference (patient-centered) seems essen-
tial. existing problems All existing generic preference-based HRQoL instruments 
(e.g. EQ-5D, HUI, SF-6D) use a small, fixed set of health attributes, forming descrip-
tions of health states that are valued by samples of the general population. When 
developing those instruments, patients’ opinions were not actively incorporated in 
the choice of attributes, nor have patients’ preferences been considered in assessing 
weights to the attributes. Compelling arguments against the currently dominant val-
uation technique, the time trade-off, have been raised by several authors. For these 
reasons, the existing instruments seem to lack credibility. an improved approach We 
developed a completely novel preference-based HRQoL measurement instrument 
that combines the strength of two existing measurement models: discrete choice 
modeling and Rasch item response theory. It is referred to as the multi-attribute 
preference response (MAPR) model. The response mechanism of the MAPR model 
is insensitive to various biases (e.g., adaptation, time preference, indifference pro-
cedure). Moreover, this is the first generic HRQoL preference-based model that is 
fully based on the perception and reporting from patients. The response task for the 
patient is to judge whether a hypothetical health-state description is considered to 
be worse or better than the health condition of the patient himself. Apart from being 
grounded on measurement theory, the tasks are easy and attractive to perform in 
a self-completion setting. Conclusion After years of dominance of ad hoc methods 
to derive values for patients’ health conditions, we present an informative HRQoL 
measurement model that overcomes credibility problems facing the conventional 
instruments.
PRM248
eaRly health eConoMiC assessMent in innoVation PaRtneRshiPs: 
lessons fRoM the euRoPean innoVation PaRtneRshiP on aCtiVe anD 
healthy ageing
de Graaf G1, Steuten L2, Pecchia L3, Boehler C4
1Panaxea BV, Enschede, The Netherlands, 2University of Washington and Panaxea bv, Seattle, 
WA, USA, 3University of Warwick, Coventry, UK, 4European Commission, Joint Research Centre, 
Sevilla, Spain
On European and national levels substantial investments are done in partnerships 
that aim to stimulate the development and implementation of healthcare innova-
tions. One such partnership is the European Innovation Partnership on Active and 
Healthy Ageing (EIP on AHA). Monitoring and assessing the societal, healthcare 
and patient impact of such large innovation partnerships is challenging for many 
reasons, including 1) the wide range of interventions developed; 2) the variety in 
